InspireMD (NYSE:NSPR) Research Coverage Started at StockNews.com

StockNews.com assumed coverage on shares of InspireMD (NYSE:NSPR) in a research report sent to investors on Wednesday morning. The firm issued a sell rating on the stock.

Separately, Lake Street Capital began coverage on InspireMD in a research note on Wednesday, December 11th. They issued a “buy” rating and a $5.00 price target for the company.

InspireMD Trading Up 0.4 %

Shares of NSPR opened at $2.58 on Wednesday. The firm has a fifty day simple moving average of $2.83 and a 200 day simple moving average of $2.73. InspireMD has a 12 month low of $1.81 and a 12 month high of $3.42. The stock has a market capitalization of $67.30 million, a price-to-earnings ratio of -3.44 and a beta of 0.99.

InspireMD (NYSE:NSPR) last announced its quarterly earnings results on Tuesday, November 12th. The company reported ($0.16) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.20) by $0.04. InspireMD had a negative return on equity of 69.42% and a negative net margin of 413.96%. The firm had revenue of $1.81 million for the quarter, compared to the consensus estimate of $1.74 million. During the same quarter in the previous year, the business earned ($0.15) earnings per share. As a group, research analysts predict that InspireMD will post -0.79 earnings per share for the current fiscal year.

Institutional Trading of InspireMD

Institutional investors have recently modified their holdings of the business. Legato Capital Management LLC bought a new position in InspireMD during the fourth quarter worth $47,000. Parkman Healthcare Partners LLC bought a new position in InspireMD in the third quarter worth approximately $279,000. Finally, Affiance Financial LLC acquired a new stake in InspireMD in the 3rd quarter valued at $492,000. Institutional investors own 44.78% of the company’s stock.

About InspireMD

InspireMD, Inc, a medical device company, focuses on the development and commercialization of MicroNet stent platform technology for the treatment of vascular and coronary diseases in Europe, Latin America, the Middle East, and Asia Pacific. The company offers CGuard carotid embolic prevention system (EPS) for use in carotid artery applications; CGuard Prime Stent System, a mesh-covered self-expanding carotid stent; and SwitchGuard NPS, a non-invasive transcarotid artery revascularization device; as well as treating acute stroke with tandem lesions.